Additionally, combination treatments targeting EGFR, ERBB2, and downstream PI3K/Akt and Ras pathways have shown downregulation of these cancer targets, along with reduced expression of JAK, STAT, and FAK1. This evidence concerns the gene AKT1 and cancer.